IL-10/Fc inhibits macrophage function and prolongs pancreatic islet xenograft survival

Transplantation

Volumn 68, Issue 11, 1999, Pages 1775-1783

  Feng, Ximin ^a   Zheng, Xin X ^b   Yi, Shounan ^a   Lehnert, Anne M ^a   Strom, Terry B ^b   O'Connell, Philip J ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b HARVARD MEDICAL SCHOOL   (United States)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL PROTOCOL; GRAFT SURVIVAL; MACROPHAGE FUNCTION; MALE; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; XENOGRAFT; XENOTRANSPLANTATION;

EID: 0033572778     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199912150-00023     Document Type: Article

References (50)

1. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993; 11: 165.
2. Florentine DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081.
3. Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 1990; 248: 1230.
4. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444.
5. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries VJ. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209.
6. Enk A H, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10: a role for IL-10 in induction of tolerance. J Immunol 1993; 151: 2390.
7. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminished the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915.
8. Ding L, Shevach EM. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 1992; 148: 3133.
9. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151: 1224.
10. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, Moore KW, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815.
11. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by IL-10. J Exp Med 1991; 174: 1549.
12. Scott P. IL-12: initiation cytokine for cell-mediated immunity. Science 1993; 260: 496.
13. Seder RA, Gazzinelli R, Sher A, Paul W. Interleukin 12 acts directly on CD4+ T cell to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sei USA 1993; 90: 10188.
14. Gerard C, Bruyns C, Marchant A, et al. Interleukin 10 reduces the release of tumour necroses factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177: 547.
15. Roussset F, Garcia E, Defrance T, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89: 1890.
16. Chen WF, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 1991; 147: 528.
17. Jinquan T, Larsen CG, Gresser B, Marsushima K, Pedersen KT. Human IL-10 is a chemoattractant for CD8+ lymphocytes and an inhibitor of IL-8-induced CD4+ T lymphocyte migration. J Immunol 1993; 151: 4545.
18. Zheng XX, Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB. Administration noncytolytic IL-10/Fc in murine models of LPS-induced septic shock and allogeneic islet transplantation. J Immunol 1995; 154: 5590.
19. Zheng XX, Steele AW, Hancock WW, et al. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol 1997; 158: 4507.
20. Lowry RP, Konieczny B, Alexander D, et al. Interleukin-10 eliminates anti-CD3 monoclonal antibody-induced mortality and prolongs heart allograft survival in inbred mice. Transplantation 1996; 27: 392.
21. Qian S, Li W, Li Y, et al. Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation 1996; 62: 1709.
22. Qin L, Chavin KD, Ding Y, et al. Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival. J Immunol 1996; 156: 2316.
23. Koulmanda M, McKenzie IFC, Sandrin MS, Mandel TE. Fetal pig islet xenografts in NOD/Lt mice: the effect of peritransplant ani-CD4 monoconal antibody and graft immunomodification on graft survival, and lock of expression of Gal (αl-3) GAl on endocrine cell. Xenotransplantation 1995; 2: 295.
24. Pierson RN, Winn HJ, Russell PS, Auchoncloss HJ. Xenogeneic skin graft rejection is especially dependent on CD4+ T cells. J Exp Med 1989; 170: 991.
25. Moses RD, Pierson RN, Winn HJ, Auchincloss HJ. Xenogeneic proliferation and lymphokine production are dependent on CD4+ helper T cells and self antigen-presenting cells in the mouse. J Exp Med 1990; 172: 567.
26. Chitilian HV, Laufer TM, Stenger KS, Shea S, Auchincloss HJ. The strength of cell-mediated xenograft rejection in the mouse is due to the CD4+ indirect response. Xenotransplantation 1998; 5: 93.
27. Simeonovic CJ, Ceredig R, Wilson JD. Effect of GK1.5 monoclonal antibody dosage on survival of pig proislet xenografts in CD4+ T cell-depleted mice. Transplantation 1990; 49: 849.
28. Wecker H, Winn HJ, Auchincloss HJ. CD4+ T cells, without CD8+ or B lymphocytes, can reject xenogeneic skin grafts. Xenotransplantation 1994; 1: 8.
29. Desai NM, Bassiri H, Kim J, et al. Islet allograft, islet xenograft, and skin allograft survival in CD8+ T lymphocyte-deficient mice. Transplantation 1993; 55: 718.
30. Wallgren AC, Parra AK, Korsgren O. The main infiltrating cell in xenograft rejection is a CD4+ macrophage and not a T lymphocyte. Transplantation 1995; 60: 594.
31. Satake M, Korsgren O, Ridderstad A, Parra AK, Wallgren AC, Moller E. Immunological characteristics of islet cell transplantation in humans and rodents. Immunol Rev 1994; 141: 191.
32. Lin Y, Vandeputte M, Waer M. Contribution of activated macrophages to the process of delayed xenograft rejection. Transplantation 1997; 64: 1677.
33. Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988; 332: 738.
34. Duncan AR, Woof JM, Partridge LJ, Burton DR, Winter G. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 1988; 332: 563.
35. Medbury HJ, Hibbins M, Lehnert AM, et al. The cytokine and histological response in islet xenograft rejection is dependent upon species combination. Transplantation 1997; 64: 1307.
36. Chen LG, Zhang BH, Harris DCH. Evidence suggesting that nitric oxide mediates iron-induced toxicity in cultured proximal tubule cells. Am J Physiol 1998; 274: F18.
37. Yi S, Feng X, O'Connell PJ. Apoptosis detection by annexin V binding: a novel method for the quantitation of cell-mediated cytotoxicity. J Immunol Methods 1998; 217: 61.
38. Tran HM, Nickerson PW, Patel A. Strom TB, Allen RDM, O'Connell PJ. Short-term suppression of the xeno-immune response with mCTLA4-Fc treatment. Xenotransplantation 1997; 4: 222.
39. Sprent J, Schaefer M, Lo D, Korngold R. Properties of purified T cell subsets II. In vivo response to class I vs. class II H-2 differences. J Exp Med 1986; 163: 998.
40. Wolf LA, Coulombe M, Gill RG. Donor antigen-presenting cell-independent rejection of islet xenografts. Transplantation 1995; 60: 1164.
41. D'Andrea A, Aste-Amezage M, Valiante NM, Ma X, Kubin M, Trinchieri G.IL-10 (IL-10) inhibits human lymphocyte interferon γ-production by suppressing natural killer cell. Stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041.
42. Chan SH, Perussia B, Gupta JW, et al. Induction of IFN-γ production by NK cell stimulatory factor (NKSF): characterization of the responder cells and synergy with other inducers. J Exp. Med 1991; 173: 869.
43. Korsgren O, Jansson L. Discondant cellular xenografts revascularized in intermediate athymic hosts fail to induce a hyperacute rejection when transplanted to immunocompetent rats. Transplantation 1994; 57: 1408.
44. Simeonovic CJ, Townsend MJ, Wilson JD, et al. Eosinophils are not required for the rejection of neovascularized fetal pig proislet xinografts in mice. J Immunol 1997; 158: 2490.
45. Sandberg JO, Benda B, Lycke N, Korsgren O. Xenograft rejection of porcine islet-like cell clusters in normal, interferon-γ and interferon-γ receptor deficient mice. Transplantation 1997; 63: 1446.
46. Benda B, Parra AK, Ridderstad A, Korsgren O. Xenograft rejection of porcine islet-like cell clusters in immunoglobilin- or Fc-receptor γ-deficient mice. Transplantation 1996; 62: 1207.
47. Korsgren O, Jansson L. Characterization of mixed syngeneic-allogeneic and syngeneic-xenogeneic islet graft rejection in mice. J Clin Invest 1994; 93: 1113.
48. Woolnough JA, Misko IS, Lafferty KL. Cytotoxic and proliferative lymphocyte responses to allogeneic and xenogeneic antigens in vitro. Aust J Exp Biol Med Sei 1979; 135: 1204.
49. Murphy B, Auchincloss HJ, Carpenter CB, Sayegh MH. T cell recognition of xeno-MHC peptides during concordant xenograft rejection. Transplantation 1996; 61: 1133.
50. Mandel TE, Koulmanda M, Cozzi E, et al. Transplantation of normal and DAF-transgenic fetal pig pancreaas into cynomolgus monkeys. Transplant Proc1997; 29: 940.